---
title: "Milestone Pharmaceuticals (MIST) Gets a Buy from Piper Sandler"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286406805.md"
description: "Piper Sandler analyst Edward Tenthoff has reiterated a Buy rating on Milestone Pharmaceuticals (MIST) with a price target of $7.00. Tenthoff, who specializes in the Healthcare sector, has an average return of 7.8% and a success rate of 40.96% on his stock recommendations. The analyst consensus for Milestone Pharmaceuticals is a Strong Buy, with a price target consensus of $7.25."
datetime: "2026-05-14T11:17:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286406805.md)
  - [en](https://longbridge.com/en/news/286406805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286406805.md)
generator: "portal-rs"
---

# Milestone Pharmaceuticals (MIST) Gets a Buy from Piper Sandler

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Milestone Pharmaceuticals, with a price target of $7.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Karyopharm Therapeutics. According to TipRanks, Tenthoff has an average return of 7.8% and a 40.96% success rate on recommended stocks. 

Milestone Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $7.25.

### Related Stocks

- [MIST.US](https://longbridge.com/en/quote/MIST.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)

## Related News & Research

- [Milestone Pharma to present at Wells Fargo annual healthcare conference](https://longbridge.com/en/news/297782738.md)
- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [BIONATION 2026 to Bring Canada’s Life Sciences Sector Together in Ottawa](https://longbridge.com/en/news/299236957.md)
- [Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co](https://longbridge.com/en/news/297931335.md)
- [Milestone Pharmaceuticals (MIST) Gets a Buy from Wells Fargo](https://longbridge.com/en/news/295788250.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**